Jordan Bertrand
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS ; CoReBio PACA, case 901, Parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
Med Sci (Paris). 2020 Nov;36(11):1095-1097. doi: 10.1051/medsci/2020205. Epub 2020 Nov 5.
A detailed analysis of the clinical benefit for 47 approved cancer drugs, using two internationally recognized assessment systems, shows essentially no correlation between clinical benefit and weekly treatment costs. This is true both in the USA and in four European countries, although prices are dramatically lower in Europe.
使用两种国际认可的评估系统，对47种已获批的癌症药物的临床益处进行的详细分析表明，临床益处与每周治疗费用之间基本没有关联。在美国和四个欧洲国家都是如此，尽管欧洲的价格要低得多。
